Ventura's Lab
@PPMC_UAB
Followers
2K
Following
9K
Media
445
Statuses
4K
Protein Folding and Conformational Diseases Lab at @UABBarcelona Lead by Prof. Salvador Ventura, CoFounder of @EurekaNBE, Director of @I3PtT
Barcelona, Catalunya
Joined June 2016
Excited to officially step into my new role as Director of the Institute of Research and Innovation Parc Taulí (I3PT) @I3ptT @iCERCA @UABBarcelona. It’s an honor to collaborate with such an incredible team! #Innovation #Research
2
3
32
Uso de #nanoanillos proteicos: estrategia prometedora contra el #coronavirus, #gripe o incluso #VirusEmergentes. Dr. Ventura: “nuestro sistema es modular y adaptable. Es una plataforma plug-and-play que puede reprogramarse rápidamente ante un nuevo brote” https://t.co/8qAjC7T8HI
0
1
2
ITCH regulates Golgi integrity and proteotoxicity in neurodegeneration | Science Advances
science.org
A shared mechanism drives Golgi fragmentation across different neurodegenerative diseases.
0
1
2
Disease-associated microglia in neurodegenerative diseases: Friend or foe? | PLOS Biology
journals.plos.org
Disease-associated microglia are a distinct, conserved microglial state associated with Alzheimer’s disease, amyotrophic lateral sclerosis and aging. This Essay discusses the dynamics, origins and...
0
2
2
Today we welcomed a group of medical students from Sweden 🇸🇪, who learned about the research and innovation we carry out at I3PT. Guided by our director, Salvador Ventura, they visited our laboratories and research facilities, including the 3D Lab. Thank you for visiting us! 👋
0
4
4
Swapping old immune cells in the brain with fresh ones could treat disease
nature.com
Nature - Replacing immune cells called microglia holds promise for addressing brain conditions such as Alzheimer’s disease.
0
0
0
🔬 A l’I3PT, la #recerca segueix avançant! El 2024 vam publicar 𝟰𝟲𝟵 articles, dels quals 𝟮𝟲𝟱 en el primer quartil, 𝟭𝟭𝟭 en el primer decil i 𝟯𝟬𝟬 disponibles en accés obert 🔓 Descobreix tots els detalls a la nostra Memòria Científica 2024! 👉 https://t.co/fqDKwMqPdM
0
5
6
🦠Un equipo internacional de científicos ha generado un nuevo nanomaterial de proteínas con forma de anillo capaz de unirse fuertemente al virus #SARSCoV2 y neutralizarlo. Vía @agencia_sinc | #COVID19
https://t.co/KbEuEg28ww
agenciasinc.es
Este nuevo estudio, que se ha publicado en la revista Advanced Healthcare Materials, destaca la polivalencia del sistema ideado para diseñar los nanoanillos, que puede integrar capacidades terapéut...
0
3
2
Apolipoprotein A-IV fibrils: structural diagnosis of mixed cardiac amyloidosis | Nature Communications
nature.com
Nature Communications - Cardiac amyloidosis is caused by misfolded protein fibrils in the heart. Here, authors describe the structure of ApoAIV amyloid found together with TTR amyloid in patient...
0
0
3
Folding-mediated secretion of pure bispecific antibodies | Nature Biotechnology
0
0
0
Glia inflammation and cell death pathways drive disease progression in preclinical and early AD | EMBO Molecular Medicine
embopress.org
imageimageGlia activation, inflammation, cell death pathways and neuronal pathologies are associated with disease progression in preclinical AD. Activation of glia cells and cell death pathways...
0
0
2
Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson’s disease: Cell
cell.com
High-purity dopaminergic progenitors were generated from human embryonic stem cells, and their safety and exploratory efficacy were evaluated in a single-center, open-label, dose-escalation phase...
0
0
1
A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features | Molecular Neurodegeneration | Full Text
molecularneurodegeneration.biomedcentral.com
Background Parkinson’s disease (PD) affects millions of people worldwide, but only 5–10% of patients suffer from a monogenic forms of the disease with Mendelian inheritance. SNCA, the gene encoding...
0
0
5
Protein misfolding in the gastrointestinal tract predicts and prognosticates neurodegenerative disease years before symptom onset | medRxiv
medrxiv.org
Background Disease-modifying therapies for neurodegenerative disorders are unlikely to succeed once symptoms emerge, as significant neuronal loss has already occurred. Accessible biomarkers that...
0
0
3
Blood tests are now approved for Alzheimer’s: how accurate are they?
0
0
0
Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case–control study - The Lancet Neurology
thelancet.com
Disproportionate Aβ clearance and ARIA-associated neuropathology localised to superficial cortical layers suggest a distinctive pattern of target engagement by aducanumab. These findings inform...
0
0
1
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment - The Lancet Neurology
thelancet.com
Treatment with anti-amyloid β antibodies is becoming standard therapy for early Alzheimer's disease, as lecanemab and donanemab received full approval in the USA, Japan, and other countries between...
0
0
0
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment - The Lancet Neurology
thelancet.com
Treatment with anti-amyloid β antibodies is becoming standard therapy for early Alzheimer's disease, as lecanemab and donanemab received full approval in the USA, Japan, and other countries between...
0
0
3
AGENDA | 𝗜𝗻𝗻𝗼𝘃𝗮𝗻𝗱𝗼 𝗽𝗮𝗿𝗮 𝗿𝗲𝗱𝘂𝗰𝗶𝗿 𝗹𝗮𝘀 𝗿𝗲𝘀𝗶𝘀𝘁𝗲𝗻𝗰𝗶𝗮𝘀 𝗮𝗻𝘁𝗶𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗻𝗮𝘀 𝗱𝗲𝘀𝗱𝗲 𝗹𝗼𝘀 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹𝗲𝘀 📆 17/10 📍 Auditori del Hospital Universitari @parctauli @I3ptT 🕙10 h 📝 https://t.co/q26guAjE1Z ℹ️ https://t.co/HJzimEIE8t
0
3
5
Para mi represento un antes y un después en mi carrera.
Los más de 7.200 investigadores e investigadoras del Programa Ramón y Cajal en sus 25 años de existencia representáis lo mejor de la ciencia española: excelencia, compromiso y capacidad de inspirar. Gracias por vuestro liderazgo, dentro y fuera de nuestro país, y por vuestra
0
0
2
#investigación | ➡️Tecnología antiviral disruptiva: #NanoanillosdeProteínas. 👉En la prueba de concepto de @IBB_UAB y @Conicet, la plataforma logra neutralizar el SARS-CoV-2 al unirse a ellos con más eficacia que anticuerpos monoclonales. ✍️ @carmenf...
diariomedico.com
En la prueba de concepto, la plataforma logra neutralizar virus SARS-CoV-2 vivos al unirse a ellos con más eficacia que anticuerpos monoclonales y otros.
0
1
1